Cancer risk similar in patients treated with TNF inhibitors, other targeted therapies
Click Here to Manage Email Alerts
PHILADELPHIA — Patients with rheumatic diseases and previous malignancy do not demonstrate a higher cancer risk with TNF inhibitors vs. other biologic and targeted synthetic DMARDs, according to data presented at ACR Convergence 2022.
“The objective of our study was to compare the risk of incident malignancy with exposure to different biological and targeted synthetic therapies in patients with rheumatic diseases who have had a previous cancer,” Juan Molina Collada, MD, of the Hospital General Universitario Gregorio Marañón, in Madrid, said during a press conference.
For the present study, Molina Collada and colleagues analyzed a cohort of patients with a history of malignancy and who had received biologic or traditional synthetic disease-modifying antirheumatic drugs (DMARDs). The researchers defined incident cancer as any cancer occurring during drug exposure, resulting in therapy discontinuation. Molina Collada and colleagues compared the incident rates of cancers in patients receiving traditional synthetic and biologic DMARDs compared with those treated with TNF inhibitors.
The analysis included 352 patients from the BIOBADASER 3.0 cohort. Among these patients, there were 32 cases of incident malignancies, included 17 cases of solid cancer, 14 non-melanoma skin cancers and one melanoma. The overall rate of cancer incidence was 27.1 events per 1,000 person-years (95% CI, 18.6-38.3).
According to Molina Collada, the overall rate of cancer “did not differ significantly” between patients receiving Janus kinase inhibitors, anti-CD20, anti-interleukin-6 or anti-CTLA-4 compared with TNF inhibitors.
“We can say that we have not found an increased risk of incident cancer in patients with rheumatic diseases and a previous cancer with any of the biological or synthetic DMARDs,” Molina Collada said. “We think this data are reassuring but should be confirmed in long-term registries.”
Collapse
Molina Collada J. Abstract 0267. Presented at: ACR Convergence 2022; Nov. 11-15, 2022; Philadelphia (hybrid meeting).
Read more about
Click Here to Manage Email Alerts